Perseus is ranked, and the performance forecast for the fiscal year ending March 2025 continues to provide clues.

Perseus <4882> is ranked (as of 9:32 AM). There has been a significant continuous decline. After the trading opened on March 31, the previously undecided Financial Estimates for the fiscal year ending March 2025 were disclosed, resulting in a limit-down yesterday. It seems that selling has continued to be a guiding factor today as well. The operating loss is estimated to be a deficit of 0.843 billion yen, while the previous period had a deficit of 0.894 billion yen. Although the pipeline activities for PPMX-T002 and PPMX-T003 are ongoing, no leads have been achieved as of now. Volume change rate top [4

Fisco JapanApr 2 08:43

Strong performance, with an upward trend in the Dow Inc average leading to dominance in buying on dips.

[Emerging Markets Individual Stocks Global Strategy] Today's Emerging Markets are expected to show a stable development. On March 31, the US Stocks market saw the Dow Inc rise by 417.86 points (+1.00%) to 42,001.76, rebounding for the first time in four days. Caution over Trump's tariffs and the diminishing expectations of a ceasefire between Russia and Ukraine weighed on stock prices. On the other hand, the unexpected rise in the Chicago Purchasing Managers' Index and the month-end and quarter-end 'dressing buys' supported the market. Today's Emerging Markets are favorable for Buy.

Fisco JapanApr 1 07:20

Shimamura, operating profit in 25/2 increased by 7.1% to 59.2 billion yen, Financial Estimates for 26/2 increased by 2.4% to 60.6 billion yen.

The performance for the fiscal year ending February 2025 announced by Shimamura <8227> shows that revenue increased by 4.8% compared to the previous period, reaching 665.3 billion 58 million yen, and operating profit increased by 7.1%, amounting to 59.2 billion 40 million yen. In the Shimamura business, with the main private brand "CLOSSHI," products that solve customer anxieties and dissatisfaction, such as the long-lasting series "Hebirote" and the sleep space Resistance series "Minmin Lab," were sold, while enhancing the added value of the high-priced PB.

Fisco JapanApr 1 04:54

Perseus Proteomics Releases FY2025 Business Forecasts Amid Licensing Challenges

TipRanksMar 31 15:02

Perseus Proteomics: Notice regarding earnings forecasts for the fiscal year ending March 31, 2025

JPXMar 31 14:30 · Announcements

Perseus Proteomics Sees FY Parent Pretax Loss Y846.00M

Dow JonesMar 31 14:30